Evaluation of Nisin F in the Treatment of Subcutaneous Skin Infections, as Monitored by Using a Bioluminescent Strain of Staphylococcus aureus

Probiotics and Antimicrobial Proteins
M de KwaadstenietLeon M T Dicks

Abstract

The potential of nisin F as an antimicrobial agent in treating subcutaneous skin infections was tested in vivo by infecting C57BL/6 mice with a bioluminescent strain of Staphylococcus aureus (Xen 36). Strain Xen 36 has the luxABCDE operon located on a native plasmid. Mice were grouped into four groups: Infected with strain Xen 36 and treated with nisin F, infected with strain Xen 36 and treated with saline (placebo), not infected and treated with nisin (control) and not infected and not treated (control). The immune systems of the mice were suppressed with deksamethasone. Mice were treated with either nisin F or sterile physiological saline 24 and 48 h after infection with subcutaneously injected S. aureus Xen 36 (4 × 10(6) CFU). Histology and bioluminescent flux measurements revealed no significant difference between infected mice treated with nisin and saline, respectively. However, infected mice treated with nisin F had an increased number of polymorphonuclear cells when compared with infected mice treated with saline. Also, not infected mice treated with nisin F had an influx of polymorphonuclear cells. Nisin F is thus ineffective in combating deep dermal staphylococcal infections. The apparent immune modulation of nisin wh...Continue Reading

References

Jul 1, 1992·Infection and Immunity·C BunceN Barg
May 4, 2004·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·R GhiselliV Saba
Feb 19, 2008·Lancet·Marc Gh BesselinkUNKNOWN Dutch Acute Pancreatitis Study Group
Apr 16, 2008·The American Journal of Emergency Medicine·Bruce M Lo, Eleanor A Erwin
May 8, 2008·Current Directions in Autoimmunity·Lawrence S Chan
Nov 21, 2008·Letters in Applied Microbiology·M De KwaadstenietL M T Dicks

❮ Previous
Next ❯

Citations

Aug 28, 2010·Journal of Biomedicine & Biotechnology·T D J Heunis, L M T Dicks
Oct 15, 2013·International Journal of Medical Microbiology : IJMM·Friedrich GötzMartin Schlag
Oct 31, 2012·Cellular and Molecular Life Sciences : CMLS·Riadh HammamiIsmail Fliss
Jan 25, 2012·Journal of Applied Microbiology·A D van StadenL M T Dicks
May 27, 2015·Nanomedicine·Renko de VriesOctavio L Franco
Feb 14, 2015·World Journal of Microbiology & Biotechnology·Rafaela Coelho CorreiaAndré Moreni Lopes
Oct 25, 2016·International Journal of Antimicrobial Agents·Varish AhmadMughees Uddin Siddiqui
Mar 1, 2010·Probiotics and Antimicrobial Proteins·T D J HeunisL M T Dicks
Jan 27, 2019·American Journal of Reproductive Immunology : AJRI·Zhifeng JiaBo Liu
Sep 26, 2020·Frontiers in Microbiology·Santosh Kumar TiwariMichael L Chikindas
Nov 24, 2019·Probiotics and Antimicrobial Proteins·Ingvild S ReinsethDzung B Diep

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.